1-3 of 3
Felix T. Garzon, MD
Close
Sort by
Journal Articles

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

Francois Guilhot, MD, Jane F. Apperley, MD, Dong-Wook Kim, MD, Gianantonio Rosti, MD, Xiaobin Yuan, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Jorge Cortes, MD
Journal: Blood
Blood (2007) 110 (11): 470.
https://doi.org/10.1182/blood.V110.11.470.470
Published: 2007
Journal Articles

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Kimmo Porkka, MD, Bengt Simonsson, MD, Herve Dombret, MD, Giovanni Martinelli, MD, Oliver G. Ottmann, MD, Chao Zhu, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Richard A. Larson, MD
Journal: Blood
Blood (2007) 110 (11): 2810.
https://doi.org/10.1182/blood.V110.11.2810.2810
Published: 2007
Journal Articles

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Nieves Diaz, MD, Eugeny A. Osmanov, MD, Yulia A. Alexeeva, MD, Mikhail Yu Byakhov, MD, Oleg N. Lipatov, MD, Sergey K. Kravchenko, MD, Ilya S. Zuzgin, MD, Felix T. Garzon, MD, Laurence Elias, MD, Philippe Solal-Celigny, MD.
Journal: Blood
Blood (2005) 106 (11): 4783.
https://doi.org/10.1182/blood.V106.11.4783.4783
Published: 2005